Skip to main content

Tiziana Life Sciences Ltd(TLSA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Tiziana Life Sciences Ltd

14-15 CONDUIT STREET
LONDON X0 W1S 2XJ GBR
P: 44-20-7495-2379
http://www.tizianalifesciences.com

Sectors & Indices

Sector
Industry
Employees

Profile

Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage. Tiziana Life Sciences PLC is based in London, United Kingdom.

Key Executives

NameTitle
Gabriele Marco Antonio CerroneChairman of the Board/Director
Kunwar ShailubhaiCEO/Chief Scientific Officer/Director

More from The Globe

number cruncher
Mining stocks paying sustainable dividends that will benefit from higher copper demand
For Number Cruncher column in Globe Investor/ROB only.
Top income investments to buy, U.S. stock ideas, and more: CIBC’s chief market technician answers your questions
It's time to hold'em or fold'em! Tax-loss selling season is quickly approaching and Sid Mokhtari, Market Technician at CIBC World Markets has come up with a list of candidates to consider unloading. Many of the stocks are down 20% or more from the start of the year.
Small caps to watch: ​​​​Calian Group and Birchcliff Energy among stocks seeing big moves as investors and analysts react to a plethora of earnings
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in January of 2019.
number cruncher
Eleven U.S. stocks with buybacks during market pessimism
For Number Cruncher column in Globe Investor/ROB only.
Bullish on Expeditors International of Washington Inc.
Monica Rizk
Small caps to watch: Boyd Group shares dive after earnings. Plus, Total Energy Services, AGT Food, Goeasy, Algoma Steel and more
{"Id":780514,"Name":"Don't expect big lift in stocks due to 'January Effect': Stephenson","Desc":"John Stephenson, President and CEO, Stephenson & Company discusses the so-called \"January effect\" and whether he thinks it will make a difference for markets in 2016.","ShortDesc":"John Stephenson, President and CEO, Stephenson & Company discusses the so-called \"January effect\" and whether he thinks it will make a...","Type":"segment","Episode":null,"AgvotCode":"E","AgvotDisclaimer":null,"QfrCode":"G","AiringOrder":null,"BroadcastDate":"2016-01-04","BroadcastTime":"08:10:15","BroadcastDateTime":"2016-01-04T08:10:15-05:00","LastModifiedDateTime":"2016-01-04T14:23:28Z","GameId":null,"Album":null,"Genres":[{"Id":154,"Name":"Commentary"},{"Id":40,"Name":"Investing"}],"Keywords":[{"Id":66203,"Name":"john stephenson","Count":139},{"Id":64202,"Name":"President","Count":273},{"Id":61326,"Name":"CEO","Count":342},{"Id":78657,"Name":"Stephenson & Company","Count":61},{"Id":70011,"Name":"january effect","Count":1},{"Id":61275,"Name":"markets","Count":1303},{"Id":61269,"Name":"stocks","Count":553},{"Id":75870,"Name":"tax-loss selling","Count":5},{"Id":63123,"Name":"small caps","Count":54},{"Id":63054,"Name":"prices","Count":20},{"Id":69699,"Name":"december","Count":2},{"Id":64558,"Name":"january","Count":0}],"Tags":[],"Images":[{"Type":"thumbnail","Url":"http://images.9c9media.com/image_asset/2016_1_4_a0629a30-951c-0133-524d-34b52f6f1279_jpg_940x529.jpg","Width":940,"Height":529}],"Authentication":{"Required":false,"Resources":null},"RatingWarnings":[],"People":[],"Funding":null,"MusicLabels":[],"BroadcastNetworks":[]}
trade secrets
The quiet stock winners hiding in plain sight
The floor of the New York Stock Exchange on May 7.
number cruncher
Eight beaten-down TSX companies growing at cheap valuations
For Number Cruncher column in Globe Investor/ROB only.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.